LONDON, UK, 21 October 2010 – SkyePharma PLC (LSE: SKP) today publishes its Interim
Management Statement. This provides an update on key matters since the half year results
announcement issued on 19 August 2010.
Pipeline and Product updates
The European Marketing Authorisation Application for Flutiform™ is progressing and preparations
continue to be made for a potential launch in 2011. Abstracts from two of the studies included in
the filing were presented by the Group’s partner Mundipharma at the 2010 Annual European
Respiratory Society Congress demonstrating effectiveness and speed of onset of the combination
of fluticasone and formoterol.
The development of Flutiform™ for Japan continues in line with expectations, with preparations
continuing for the initiation of Phase III clinical trials, which are expected to commence shortly.
The Group continues to investigate whether there is a viable way forward for Flutiform™ in the
United States, including identifying potential partners to finance any additional work required.
The Board continues to anticipate that revenues for the year as a whole will show modest growth
compared with 2009, although manufacturing revenues for Q4, 2010, will be lower than the
Board’s previous expectations.
Dr. Axel Müller was appointed Chief Executive Officer of the Group on 23 August 2010.
Following the handover to Dr Müller, Dr. Ken Cunningham stepped down as a Director of the
Group as planned on 30 September 2010.
Dr Axel Müller, Chief Executive Officer of SkyePharma, said, “SkyePharma has continued to
make good progress, with the underlying business maintaining a solid performance during the
third quarter. In my first few weeks as CEO I have been impressed by the potential across
SkyePharma, both in terms of opportunities for Flutiform™ and to leverage the Group’s first class
drug delivery technologies and skills.”
For further information please contact:
Axel Müller, Chief Executive Officer +44 207 491 1777
Peter Grant, Chief Financial Officer
Jonathan Birt/Susan Quigley +44 207 831 3113
About SkyePharma PLC
Using its proprietary drug delivery technologies, SkyePharma develops new formulations of
known molecules to provide a clinical advantage and life-cycle extension. The Group has twelve
approved products in the areas of oral, inhalation and topical delivery. The Group’s products are
marketed throughout the world by leading pharmaceutical companies. For more information, visit